Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants
Compared with receipt of a SD-IIV4 during pregnancy, this large study did not identify any pregnancy, birth, or neonatal/infant safety concerns following receipt of a RIV4 during pregnancy and demonstrates that the safety of RIV4 in pregnancy was similar to SD-IIV4. This study provides additional evidence regarding the safety of influenza vaccination in pregnant persons and further supports ACIP and ACOG recommendations that all pregnant persons receive an inactivated or recombinant influenza vaccine.
Authors
- Oxana Talanova
- Amber Hsiao (ORCID: https://orcid.org/0000-0003-2295-0886)
- Nicola P. Klein (ORCID: https://orcid.org/0000-0003-1777-4814)
- John Hansen (ORCID: https://orcid.org/0000-0001-7891-2673)
- Bruce Fireman (ORCID: https://orcid.org/0000-0003-1652-985X)
- Alexandre Selmani (ORCID: https://orcid.org/0000-0002-7709-0142)
- Sonja Gandhi‐Banga (ORCID: https://orcid.org/0000-0003-3581-9318)
- Ajinkya Inamdar
- Ruvim Izikson
- Arnold Yee
- Heidi Kabler (ORCID: https://orcid.org/0000-0002-6894-0213)
- Ned Lewis
Institutions
- Epson (United States) (US)
- Kaiser Permanente (US)
- Sanofi (Canada) (CA)
- BioNTech (United States) (US)
Publication Details
- Journal
- AJOG Global Reports
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1016/j.xagr.2024.100395
- Citations
- 4
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.55
Funders
- Pfizer
- GlaxoSmithKline
- Sanofi
- Seqirus